← Leaderboards
Candelaria Gomez-Manzano
University Of Tx Md Anderson Can Ctr
$2,523,797
Attributed
$4,466,433
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $882.9K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,466,433 · 5
By mechanism
R01$3,655,964 · 2
P50$409,917 · 1
R21$229,309 · 1
U54$171,243 · 1
Top collaborators
- Juan Fueyo8 shared
- Frank C Marini5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Juan Fueyo$8,546,462
- Jian Hu$8,609,311
- John F De Groot$2,436,888
- Anil K Sood$29,572,737
- Joseph H McCarty$11,299,070
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsBrain NeoplasmsMediatingPre-ClinicalClinical TrialsGliomaMalignant NeoplasmsImmunocompetentRecurrenceOperative Surgical ProceduresClinical DataGlioblastomaLaboratoriesMalignant GliomaCancer TherapyCharacteristicsMouse ModelInjectionsOncolytic AdenovirusInfectionCombined Modality TherapyImmunePathway Interactions
Grant awards (18)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$370,575
R01 · FY2025 · CA
Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses$229,309
R21 · FY2025 · CA · contact PI
Animal Core (Core D)$201,174
P50 · FY2025 · CA · contact PI
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$81,881
R01 · FY2025 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$352,047
R01 · FY2024 · CA
Animal Core (Core D)$208,743
P50 · FY2024 · CA · contact PI
NCI Diversity Supplement: Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$69,324
R01 · FY2024 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$363,164
R01 · FY2023 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$363,164
R01 · FY2022 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants$370,575
R01 · FY2021 · CA
Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer$64,219
U54 · FY2021 · CA · contact PI
Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer$69,122
U54 · FY2020 · CA · contact PI
Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer$37,902
U54 · FY2019 · CA · contact PI
Role of TEMs in brain tumor dispersal$335,325
R01 · FY2014 · NS · contact PI
Role of TEMs in brain tumor dispersal$326,858
R01 · FY2013 · NS · contact PI
Role of TEMs in brain tumor dispersal$338,713
R01 · FY2012 · NS · contact PI
Role of TEMs in brain tumor dispersal$338,713
R01 · FY2011 · NS · contact PI
Role of TEMs in brain tumor dispersal$345,625
R01 · FY2010 · NS · contact PI